OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...

In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients ...

Gastrointestinal involvement is common among patients with EGPA, with eosinophilic tissue infiltration, weight loss, and myalgia identified as significant predictors.

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

It’s not known why some people develop EG/EoD, but many people with the condition also have a history of allergies. It may take time for EG/EoD to be diagnosed, which can be frustrating and difficult ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Background & Aims: Eosinophils are the main inflammatory effector cells that damage gastrointestinal tissue in eosinophilic gastrointestinal diseases (EGIDs). Activation of the OX40 pathway aggravates ...

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of vasculitis, meaning it causes inflammation in small and medium sized blood vessels, which can result in damage to organs ...

Researchers from Revolo Biotherapeutics Ltd. recently presented preclinical data for IRL-201104, a clinical-stage ...

Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis,” published in the February 2025 ...

Sandra Koch, DVM, MS, DACVD, talks about the 4 reaction patterns associated with feline atopic skin syndrome, commonly known as environmental allergies or atopic dermatitis ...